The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Pre-clinical & Translational Research in Multiple Myeloma
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.
Only pre-clinical projects with a focus on these areas of interest will be considered for Pfizer support at this time:
• Correlation between soluble B-cell Maturation Antigen (sBCMA) at baseline with FLC, M-spike, deepness of overall response, MRDnegativity, and response to prior therapy
• Understanding the kinetics of sBCMA vs long-term responses (e.g., DoR, PFS, OS) in the context of bispecific treatment
• Mechanisms of resistance (e.g., role of sBCMA in resistance/relapse; downregulation of membrane bound BCMA; T-cell exhaustion)
• Correlation between Soluble BCMA and BCMA expression on myeloma cells (including assessment of gamma secretase activity)
• Impact of prior treatment with BCMA-targeting agents on BCMA expression and sBCMA levels (including whether these prior treatments lead to BCMA mutations)
• Mechanistic understanding of the impact of anti-myeloma agents (e.g., IMiDs, anti-CD38, proteasome inhibitors, dexamethasone) on elranatamab-mediated T-cell activation and anti-myeloma activity
• Exploring in-vitro or in-vivo novel combinations with elranatamab (PF06863135) with a focus on drugs that are not currently SOC in myeloma
• Immunosuppressive mechanisms in the bone marrow that negatively impact bispecific (elranatamab) activity
• Comparative analysis of bone marrow aspirate transcriptomes between responders and non-responders to elranatamab
Full Proposal Grant Application due date: September 28, 2021
Geographic Scope: Global – all regions and countries included
• The institution and principal investigator (PI) must be based in one of the eligible countries noted above. • Only organizations are eligible to receive grants, not individuals or medical practice groups. • The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy. • Applicant must be affiliated with a host institution
Individual projects requesting up to $150,000 will be considered. The estimated total available budget related to this RFP is $500,000.
Compound-only requests (with no funding requested) may also come through this RFP.